LeMaitre Vascular

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LeMaitre (LMAT) delivered earnings and revenue surprises of -10.71% and 2.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Misses Q3 Earnings and Revenue Estimates

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q3 2022 Results Conference Call October 27, 2022 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer David Roberts - President Conference Call Participants Michael Sarcone - Jefferies Brooks O'Neil - Lake Street Capital Purnima Malik - Stifel Michael Petusky - Barrington Research James Sidoti - Sidoti & Company Scott Henry - ROTH Capital Javier Fonseca - Spartan Capital Operator Good day, and welcome to the LeMaitre Vascular Incorporated's Third Quarter 2022 Earnings Conference Call.

LeMaitre Vascular, Inc. (LMAT) Q3 2022 Earnings Call Transcript

BURLINGTON, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2022 results, announced a $0.125/share quarterly dividend and provided guidance.

LeMaitre Q3 2022 Financial Results

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: LeMaitre Vascular (LMAT) Q3 Earnings Expected to Decline

BURLINGTON, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2022 financial results on Thursday, October 27, 2022, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce Third Quarter 2022 Earnings Results October 27, 2022

We reiterate the buy call on LeMaitre Vascular. The company's capital management strategies continue to yield double-digit ROI from its invested capital.

LeMaitre Vascular: Reiterate Buy Thesis Following Strong Q2 Numbers

BURLINGTON, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022, at 4:40 PM ET at the Sheraton New York Hotel, New York.

LeMaitre to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Zimmer Biomet Hlds

ZBH vs. LMAT: Which Stock Is the Better Value Option?

ZBH vs. LMAT: Which Stock Should Value Investors Buy Now?

BURLINGTON, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022, at 12:00 PM ET at the InterContinental Hotel, Boston.

LeMaitre to Present at the Canaccord Genuity 42nd Annual Growth Conference

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q2 2022 Earnings Conference Call July 28, 2022 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chairman and Chief Executive Officer David Roberts - President Conference Call Participants Zach Weiner - Jefferies Brooks O'Neil - Lake Street Capital Purnima Malik - Stifel Matthew Mishan - KeyBanc Michael Petusky - Barrington Research Jim Sidoti - Sidoti & Company Javier Fonseca - Spartan Capital Operator Welcome to the LeMaitre Vascular Q2 2022 Financial Results Conference Call.

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q2 2022 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of -9.38% and 2.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Lags Q2 Earnings Estimates

BURLINGTON, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2022 results, announced a $0.125/share quarterly dividend and provided guidance.

LeMaitre Q2 2022 Financial Results

LeMaitre Vascular Inc. ( LMAT , Financial) has been on a roll—it has generated robust financial results and metrics that produced a high GF Score. But the share price has been in a slump.

A Debt-Free and Fairly Valued Medical Devices Company

BURLINGTON, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2022 financial results on Thursday, July 28, 2022, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce Second Quarter 2022 Earnings Results July 28, 2022

LeMaitre has been beaten down lately, however, the pullback lends significant opportunity to add to a long-term compounder. The company has a differentiated value proposition from an investment perspective and operates within a niche segment.

LeMaitre Vascular: 16% Return Objective From Idiosyncratic Risk Premia

BURLINGTON, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Sidoti Summer Small Cap Virtual Conference on Wednesday, June 15, 2022, at 2:30 PM ET.

LeMaitre to Present at the Sidoti Summer Small Cap Virtual Conference

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q1 2022 Earnings Conference Call April 28, 2022 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chairman and Chief Executive Officer Dave Roberts - President Conference Call Participants Zach Weiner - Jefferies Brooks O'Neil - Lake Street Capital Mike Petusky - Barrington Research Jim Sidoti - Sidoti Javier Fonseca - Spartan Capital Operator Welcome to the LeMaitre Vascular Q1 2022 Financial Results Conference Call.

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q1 2022 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of -3.57% and 1.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Q1 Earnings Miss Estimates

BURLINGTON, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2022 results, announced a $0.125/share quarterly dividend and provided guidance.

LeMaitre Q1 2022 Financial Results

BURLINGTON, Mass., April 15, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2022 financial results on Thursday, April 28, 2022, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce First Quarter 2022 Earnings Results April 28, 2022

LeMaitre Vascular continues to be a solid secular growth play in the vascular business.

LeMaitre Vascular: Steady As She Goes

LeMaitre Vascular could be a hidden gem for dividend growth investors.

Is This Overlooked Stock a Buy After Its Dividend Hike?

BURLINGTON, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 10:15 AM ET.

LeMaitre to Present at the Needham Virtual Healthcare Conference

BURLINGTON, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today announced that it has joined the NASDAQ US Broad Dividend Achievers Index. The index is comprised of US securities with at least ten consecutive years of increasing annual regular dividend payments. In 2011, LeMaitre's first year of dividends, the annual payout per share was $0.08. In 2021, LeMaitre paid $0.44 per share, representing 18.6% compounded annual dividend growth over the decade. A further increase was announced in February 2022, bringing the quarterly payout to $0.125 per share, payable on March 24, 2022. George W. LeMaitre, Chairman and Chief Executive Officer, said, “We're pleased to see NASDAQ add us to their prestigious Dividend Achievers Index, a select group of 373 companies. Our growing profitability has enabled us to consistently increase our dividends since 2011. By paying dividends we re-affirm our commitment to profitability and an improving balance sheet.” About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. LeMaitre is a registered trademark of LeMaitre Vascular, Inc., and the NASDAQ US Broad Dividend Achievers Index is a registered trademark of Nasdaq. For more information about the Company, please visit http://www.lemaitre.com.

LeMaitre Joins NASDAQ Dividend Achievers Index – 10 Years of Dividend Increases

LeMaitre Vascular's (LMAT) CEO George LeMaitre on Q4 2021 Results - Earnings Call Transcript

News for LeMaitre Vascular Stock (LMAT)